Atacama Therapeutics is focused on developing innovative treatments for serious dermatological conditions, with an initial emphasis on acne vulgaris. The company is conducting a proof-of-concept trial for its lead product, AT-5214, which is designed to address the significant unmet medical need in this area. Acne vulgaris is a common skin condition characterized by increased sebum production, which is influenced by sympathetic activation. Atacama's approach aims to mitigate the underlying mechanisms that contribute to this condition, particularly through the modulation of nicotinic acetylcholine receptors.

AT-5214, the S-enantiomer of mecamylamine, acts as a selective inhibitor of nicotinic acetylcholine receptors, potentially reducing sympathetic ganglion activity while minimizing parasympathetic side effects. This targeted mechanism is thought to decrease sebum production and improve symptoms associated with acne vulgaris. Additionally, AT-5214 has shown promise in clinical studies for conditions like hyperhidrosis, where it effectively reduced sweat and sebum secretion. By addressing the sympathetic stimuli that drive sebum production, Atacama Therapeutics aims to provide a novel therapeutic option for patients suffering from acne vulgaris and related dermatological issues.

United States

Atacama Therapeutics is a dermatology company focused on advancing treatment for skin and musculoskeletal diseases. The company's pipeline includes AT-5214, a small molecule drug for the treatment of malignant hypertension.

Atacama Therapeutics

Company Details